(Reuters) - NEW YORK, July 16 - Barr Pharmaceuticals Inc. said on Monday it is challenging patents on Sepracor Inc.'s asthma drug Xopenex in its effort to sell a generic version of the product. Sepracor has filed suit in the U.S. District Court of Delaware to prevent Barr from selling its generic, Barr said.
Xopenex, one of Sepracor's biggest-selling products, had U.S. sales of about $610 million for the 12 months ended in May, Barr said.
Read more at Reuters.com Government Filings News
Xopenex, one of Sepracor's biggest-selling products, had U.S. sales of about $610 million for the 12 months ended in May, Barr said.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment